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Failure of Hippocampal Deactivation during Loss Events in Treatment-
Resistant Depression 
 
 
Blair A. Johnston,1 Serenella Tolomeo,1 Victoria Gradin,2 David Christmas,3 Keith 
Matthews,1,3 J. Douglas Steele1,3 
 
Abstract 
Major Depressive Disorder is characterised by anhedonia, cognitive biases, ruminations, 
hopelessness and increased anxiety. Blunted responses to rewards have been reported in a 
number of recent neuroimaging and behavioural studies of Major Depressive Disorder. In 
contrast, neural responses to aversive events remain an under-studied area. Whilst 
Selective Serotonergic Reuptake Inhibitors are often effective in treating Major 
Depressive Disorder, their mechanism of action remains unclear. Following a series of 
animal-model investigations of depressive illness and serotonergic function, Deakin and 
Graeff predicted that brain activity in Major Depressive Disorder patients is associated 
with an overactive dorsal raphe nucleus with overactive projections to the amygdala, 
periaqueductal grey and striatum, and an underactive median raphe nucleus with 
underactive projections to the hippocampus. Here we describe an instrumental loss-
avoidance and win-gain reinforcement learning functional magnetic resonance imaging 
study with 40 highly treatment-resistant Major Depressive Disorder patients and never-
depressed controls. The dorsal raphe nucleus/ periaqueductal grey region of the midbrain 
and hippocampus were found to be overactive in Major Depressive Disorder during 
unsuccessful loss-avoidance although the median raphe nucleus was not found to be 
underactive.  Hippocampal overactivity was due to a failure to deactivate during loss 
events in comparison to controls, and hippocampal over-activity correlated with 
depression severity, self-report ‘hopelessness’ and anxiety. Deakin and Graeff argued that 
the median raphe nucleus normally acts to inhibit consolidation of aversive memories via 
the hippocampus and this system is underactive in Major Depressive Disorder, 
facilitating the development of ruminations, whilst the dorsal raphe nucleus system is 
engaged by distal cues predictive of threats and is overactive in Major Depressive 
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Disorder. During win events the striatum was underactive in Major Depressive Disorder. 
We tested individual patient consistency of these findings using within-study replication. 
Abnormal hippocampal activity correctly predicted individual patient diagnostic status in 
97% (sensitivity 95%, specificity 100%) of subjects, and abnormal striatal activity 
predicted diagnostic status in 84% (sensitivity 79%, specificity 89%) of subjects. We 
conclude that the neuroimaging findings were largely consistent with Deaken and 
Graeff’s predictions, abnormally increased hippocampal activity during loss events was 
an especially consistent abnormality, and brainstem serotonergic nuclei merit further 
study in depressive illness. 
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Introduction 
In major depressive disorder (MDD), characteristic cognitive and attentional biases are 
directed towards aversively valenced information (associated with depressive 
ruminations, hopelessness, perceptions of helplessness, anxiety and irritability) and away 
from rewarding stimuli (anhedonia) (Beck, 1979). This is consistent with observations 
that neural responses to rewards are blunted and responses to aversive stimuli increased, 
with a recent systematic meta-analysis concluding that both abnormalities are reversed by 
antidepressant treatment (Ma, 2014). Previously we reported underactive striatal 
responses to rewarding events in MDD (Steele et al., 2007; Kumar et al., 2008; Gradin et 
al., 2011) supported by a recent neuroimaging meta-analysis (Zhang et al., 2013) and 
behavioural meta-analysis (Huys et al., 2013). 
In contrast to studies on rewards, there are far fewer studies on the neural 
responses to aversive stimuli in MDD and none to our knowledge on patients with 
treatment-resistant MDD using instrumental loss-avoidance learning paradigms. A few 
studies have reported responses to rewarding and aversive stimuli in depression (Knutson 
et al., 2008; Stoy et al., 2012; Ubl et al., 2015) using a monetary incentive delay task 
where task difficulty is based on reaction times and reported differing abnormalities.  
Neural responses to aversive stimuli are particularly relevant given the link between 
aversive information processing and serotonergic function (Gray and McNaughton, 2000; 
Boureau and Dayan, 2011; Deakin, 2013) and the efficacy of Selective Serotonergic 
Reuptake Inhibitors (SSRIs) for many but not all patients. 
Error commission is aversive (Hajcak and Foti, 2008) and it has been reported 
that depressed patients have an abnormal response to feedback of poor behavioural 
performance (Elliott et al., 1997; Murphy et al., 2003; Roiser et al., 2012). 
Electrophysiological studies of behavioural errors in MDD have reported an abnormally 
increased Error Related Negativity (Chiu and Deldin, 2007; Holmes and Pizzagalli, 2010; 
Georgiadi et al., 2011) and an abnormally increased Feedback Related Error signal which 
may be associated with enhanced avoidance learning (Cavanagh et al., 2011).  Whilst 
abnormal responses to rewarding events imply abnormal (Nestler and Carlezon, 2006) 
and blunted dopaminergic reward learning activity (Kumar et al., 2008; Gradin et al., 
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2011) although see (Huys et al., 2013), the role of putative serotonergic abnormalities in 
MDD remains very unclear (Boureau and Dayan, 2011; Faulkner and Deakin, 2014). 
Following a series of animal-model studies focusing on serotonergic function, 
Deakin and Graeff predicted that depressive illness involves an overactive dorsal raphe 
nucleus (DRN) with overactive projections to the amygdala (anxiety), periaqueductal 
grey (PAG; helplessness), and caudate/striatum (anhedonia), and an underactive median 
raphe nucleus (MRN) with underactive projections to the hippocampus (ruminations) 
(Deakin and Graeff, 1991; Deakin, 2013). The DRN-PAG-amygdala-striatum hypothesis 
is a particularly strong test of Deaken and Graeff’s theory because such observations are 
highly unlikely according to a contrary theory of MDD as a ‘serotonin deficiency’ 
disorder (Deakin, 2013). 
We chose loss-avoidance and reward-gain instrumental learning tasks because 
‘loss’ is an aversive event prominently linked to MDD clinically (Beck, 2008) and 
blunted striatal reward-gain activity has been reported in many studies of depression 
(Pizzagalli et al., 2009; Stoy et al., 2012; Zhang et al., 2013).  Notably we focused only 
on unsuccessful loss-avoidance events, as loss events are experienced as aversive, in 
contrast to successful loss-avoidance which has similarities to a reward (Rolls, 1999).  
Whilst many studies on mood disorder involve recovered, previously ill patients or 
healthy subjects with transient mood induction, which may or may not reflect depressive 
illness, we chose to study treatment-resistant depressive illness given the remarkably high 
prevalence of chronic disability associated with mood disorder (Whiteford et al., 2013).  
Whilst Deakin and Graeff made predictions about depression in general and not 
treatment-resistant illness in particular, we used Deakin and Graeff’s framework to 
construct hypotheses about such patients, as this population may have more consistent 
abnormalities than treatment responsive patients. 
The following three groups of hypotheses were tested: i) the DRN/PAG region of 
the midbrain, striatum and amygdala have abnormal activity in MDD (Deakin, 2013) 
during unsuccessful loss-avoidance events; ii) the hippocampus is abnormally increased 
in activity and the MRN region of the midbrain abnormally decreased in activity in MDD 
(Deakin, 2013) during unsuccessful loss avoidance; iii) the striatum (which includes the 
nucleus accumbens) is underactive in MDD during rewarding events (Kumar et al., 2008; 
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Gradin et al., 2011; Stoy et al., 2012; Deakin, 2013). We also tested for correlations 
between loss and win event brain activity and ratings of illness severity and treatment-
resistance for the patient group alone, to determine if any correlations were consistent 
with between groups (MDD versus control) abnormalities. 
Standard fMRI analyses consist of testing the null hypothesis of no difference 
between patient and control groups.  Despite this approach identifying disorder-related 
average group abnormalities, these are rarely consistent enough to make individual 
patient inferences.  Therefore, to estimate the specificity of abnormal patterns of 
activation/deactivation for individual patients, we generated a predictive model and used 
within-study replication to form an unbiased estimate of consistency. 
 
Materials and methods 
The study was approved by the local Ethics Committee (the East of Scotland Research 
Ethics Service) and written informed consent was obtained from all volunteers. Forty one 
adults with treatment-resistant MDD and controls were recruited: twenty adults with 
treatment-resistant MDD from the Advanced Interventions Service in Dundee, a tertiary 
level UK-wide service specialising in treatment-resistant MDD receiving referrals from 
NHS consultant psychiatrists throughout the UK. Data from one control had to be 
excluded from the analysis due to a failure to perform the fMRI task meaning data from 
40 subjects were included in the analyses. Diagnosis was made according to MINI PLUS 
(v5.0) criteria (Sheehan and Lecrubier, 1992). Each patient’s clinical history was 
reviewed with respect the number of failed antidepressant treatment trials to quantify 
treatment-resistance in accordance with the Massachusetts General Hospital staging 
(MGH-S) method (Fava, 2003). Exclusion criteria were any potentially confounding 
diagnosis: including other primary psychiatric disorder, substance misuse or significant 
head injury.  Twenty-one healthy controls with no lifetime history of MDD were 
recruited, mostly from partners, relatives and friends of patients and underwent 
psychiatric assessment using the MINI PLUS. None of the controls had a current or past 
psychiatric or neurological disorder and none were taking medication. Syndrome severity 
was assessed using the Montgomery-Åsberg Depression Rating Scale (Montgomery and 
Asberg, 1979), 17-item Hamilton Depression Rating Scale (HAM-D) (Hamilton, 1960), 
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Hospital Anxiety and Depression Rating – Anxiety Scale (HAD-A) (Zigmond and Snaith, 
1983), Beck Depression Inventory-II (BDI) (Beck et al., 1996) and Beck Hopelessness 
Scale (BHS) (Beck et al., 1974).  All MDD and control volunteers included in the 
analyses had a predicted pre-morbid Full Scale Intelligence Quotient above 106 as 
assessed by the National Adult Reading Test. Handedness was assessed using the 
Edinburgh Handedness Inventory (Oldfield, 1971). Apart from 2 left-handed subjects in 
the control group and 1 and 3 ambidextrous subjects in the control and patient groups 
respectively, all subjects were right-handed. 
 
Image acquisition 
For each participant functional whole-brain images were acquired using a 3T Siemens 
Magnetom TimTrio Syngo scanner using an echo-planar imaging sequence with the 
following parameters: TR = 2500 ms, TE = 30 ms, flip angle = 90°, FOV = 224 mm, 
matrix = 64 x 64, 37 slices, voxel size 3.5x3.5x3.5 mm. The first four blood-oxygen-level 
dependent volumes were discarded as standard due to transient effects. 
 
Paradigm 
The fMRI paradigm was a modified version of the Pessiglione task (Pessiglione et al., 
2006) which incorporated rewarding (‘win’), neutral (‘no change’) and aversive (‘loss’) 
outcomes. One pair of fractal images was associated with each potential outcome type; 
win, loss or neutral. Associations between outcomes and fractal shapes were randomised 
across subjects. Win trials had the possible outcomes ‘you win’ or ‘nothing’ (no change) 
and loss trials had the possible outcomes ‘you lost’ or ‘nothing’. A neutral condition with 
outcomes ‘look’ or ‘nothing’ was included whereby no change occurred regardless of 
choice. Participants were not informed that the win and loss fractal pairs had one option 
with a fixed ‘high’ (0.7) probability of winning or losing and the other option with a fixed 
‘low’ probability (0.3). Subjects understood that the goal of the task was to maximise 
winning and minimise loosing ‘vouchers’ through trial and error but that no actual 
payments would be made. At the beginning of each trial subjects choose between a pair 
of fractal images, with the order of the fractal images randomly assigned to the left or 
right of the screen. Three seconds after the beginning of each trial the images were 
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replaced with a fixation cross; a small black “+” in the centre of a white background, then 
feedback of the outcome was given.  The sequence and timing of win and loss pairs of 
fractal stimuli was optimised for detection of the signals of interest using ‘optseq2’ 
(http://surfer.nmr.mgh.harvard.edu/optseq/); during the inter-trial interval a fixation cross 
was displayed for a variable amount time (jitter) ranging between 3 and 13.75 seconds.  
A summary of the task is shown in Fig. 1. 
 
Image pre-processing 
All scans were visually inspected for artefacts (McRobbie et al., 2010) and pre-
processing done using SPM8 (http://www.fil.ion.ucl.ac.uk/spm). Images were realigned 
to the first image in each time series and co-registered to the SPM8 Montreal 
Neurological Institute echo planar imaging template. The average realigned co-registered 
image for each subject was used as a template to normalise each realigned and co-
registered volume to the SPM8 echo planar imaging template image and smoothed. 
  
Image analyses 
Event-related random effects designs were used for analyses. The times of each category 
of feedback were modelled as truncated delta functions and convolved with the SPM8 
canonical haemodynamic response function without time or dispersion derivatives. 
Vectors representing these events were entered into first level analyses for each subject 
and as usual, six motion realignment parameters calculated during realignment were 
entered as covariates of no interest to remove any residual motion related variance. Two 
images were generated during the first level analysis, a ‘win’ image as [(win − nothing) − 
(look − nothing)] and a ‘loss’ image as [(loss − nothing) − (look − nothing)]. 
The win and loss images for each subject were separately entered into second 
level analyses to test for within-group (one-group t-test) activations/deactivations and 
between-group differences (MDD versus controls, two-group t-tests).  The patient group 
was investigated further by testing for correlations with syndrome severity (MADRS, 
HAM-D, HAD-A, BDI, BHS) and treatment resistance (MGH-S) with the object of 
determining whether any of the categorical between group (MDD versus control) 
differences for a given brain region were consistent with patient group-only correlations. 
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Significance was defined as P < 0.01 at a whole brain, Family-Wise Error corrected level, 
with simultaneous requirements for voxel threshold (P < 0.05) and minimum cluster 
extent ( > 120 voxels) identified using a popular Monte-Carlo method (Slotnick et al., 
2003).  All figures are shown at this threshold. 
The DRN forms a rostrocaudal ventral midline column and is part of the PAG (Le 
Maitre et al., 2013).  The PAG activates in response to aversive stimuli (McNally et al., 
2011; Roy et al., 2014) as do ‘clocklike’ serotonin neurones in the DRN (Schweimer and 
Ungless, 2010).  The DRN projects to various regions such as the amygdala and striatum 
(Deakin, 2013) and the remainder of the PAG similarly also projects to the amygdala but 
indirectly via paths including the thalamus (McNally et al., 2011).  Whilst the DRN can 
be discriminated from the rest of the PAG using high resolution histological techniques, it 
was not considered practical to discriminate the DRN from the rest of the PAG given 
fMRI spatial resolution and similar responses to aversive stimuli.  Our DRN region 
should therefore be viewed as a combination of the DRN and PAG.  The DRN can be 
confused with the more inferior MRN so we followed recommended DRN identification 
criteria (Kranz et al., 2012): to identify the DRN we required an activation locus to be 
included within a spherical region of interest centred at the level between the superior and 
inferior colliculi 6 mm in diameter (Fig. 2B) (Kranz et al., 2012) and in addition required 
that this activation was in response to aversive (Schweimer and Ungless, 2010; Deakin, 
2013) loss events. Kranz’ corresponding definition for the MRN, to reliably delineate the 
MRN from the DRN, is a region of interest in the rostral pons (Kranz et al., 2012).  We 
did not identify significant activity in this region. 
 
Calculation of specificity of findings for individuals  
Conventional null hypothesis testing is important for identifying group level 
abnormalities but not ideal for testing the consistency of findings for individual patients. 
We therefore used a combination of ‘feature selection’ (automated identification of brain 
regions), machine learning (to optimally combine information from the selected brain 
regions) and within-study replication (cross-validation) to make unbiased inferences 
about individual patients (Johnston et al., 2014). Using ‘one left out cross validation’ 
there were two stages to the calculation: ‘training’ of an optimal predictor using n − 1 
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subjects’ images followed by testing using the ‘left out’ data set.  Feature selection was 
only adjusted during training and consisted of varying the threshold on a t-test, a method 
which involved calculating a standard two-group t-test on each training dataset (omitting 
the testing data) using standard SPM routines (Johnston et al., 2014). Machine learning 
was done using a Matlab (Mathworks Inc.) Support Vector Machine toolbox 
(Schwaighofer, 2001) with a Gaussian kernel. During the testing stage, accuracy, 
sensitivity and specificity were calculated for all subjects. 
 
Results 
 
Participants 
Age and IQ did not differ significantly (t-test, P > 0.1) between MDD and control groups 
and gender was not significantly different (chi-square test). There were no significant 
differences in task performance between groups implying that neuroimaging differences 
cannot be attributed to a failure to perform the task.  The average HAM-D, MADRS and 
BDI illness severity ratings in the TRD group (Table 1) indicated depression severity in 
the moderate range. The mean MGH-S score of 13.2 indicates these patients were highly 
treatment resistant with the score being comparable to a previous assessment of patients 
attending the specialist Advanced Interventions Service (15.5), and significantly greater 
than typical UK secondary care (CMHT) psychiatric (5.3) and primary care (0.5) 
treatment-resistance levels (Hazari et al., 2013).  Seventeen MDD participants were 
treated with one or more anti-depressant medications (venlafaxine (6), sertraline (3), 
trazodone (3), citalopram (2), fluoxetine (2), mirtazapine (2), isocarboxazid (1), L-
tryptophan (1), phenelzine (1), and tranylcypromine (1); seven patients received anti-
psychotic medications (quetiapine (6) and chlorpromazine (1)) and three lithium 
augmentation reflecting typical clinical practice with treatment-resistant MDD.
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Loss trials 
During loss events using one group t-tests, controls activated the bilateral insula 
(−40,18,−24), (38,16,−18) without significant activation in the DRN region of the 
midbrain, and deactivated a cluster including peaks at the bilateral hippocampus 
(34,−26,−10), (−32,−26,−10), subgenual anterior cingulate (−10,22,−10), (12,24,−12) and 
bilateral nucleus accumbens (−10,6,−10), (12,8,−14). 
In contrast, patients activated the DRN/PAG region of the midbrain (0,−20,−2), 
bilateral insula (−42,18,−2), (38,18,8) and amygdala (−28,−6,−8), and deactivated a 
cluster including peaks at the bilateral subgenual anterior cingulate (−12,36,−10), 
(14,34,−6), bilateral nucleus accumbens (10,16,−10), (−8,14,−6) but not hippocampus. 
Using two-group tests, during loss events MDD patients had increased activation 
within a cluster including peaks at the DRN/PAG region of the midbrain (0,−20,−2), 
hippocampus (−32,−28,−10), amygdala (−28,−6,−8) and insula (+/−46,−2,2), whereas 
controls had increased activity in the nucleus accumbens (10,16,−10).  This is shown in 
Fig. 2 and Supplementary Table 1. Increasing the voxel significance threshold to P < 
0.001 resulted in a distinct anatomical cluster within the hippocampus at (−32,−28,−10) 
with a cluster size of 576 voxels. 
 
Win trials 
During win events using one group t-tests, controls activated a cluster including peaks at 
the nucleus accumbens/inferior caudate (−2,8,−2), (−12,8,−8), (12,10,−10), subgenual 
anterior cingulate (−4,52,−8), posterior cingulate (−2,−16,40), (−6,−50,24) and 
deactivated lateral cortical regions (50,22,14), (−42,20,28), (−40,−60,48). 
In contrast, patients activated fewer regions including the bilateral subgenual 
anterior cingulate (−14,58,0), (10,46,−2), bilateral insula (−48,4,−6), (50,0,0), bilateral 
amygdala (−28,2,−16), (26,0,−12), bilateral hippocampus (−30,−14,−10), (42,−16,−10) 
and deactivated the bilateral dorsolateral prefrontal cortex (44,16,26), (−58,20,26). 
Using two-group t-tests, during win events controls had significantly increased 
activity in the subgenual anterior cingulate (−2,52,4), nucleus accumbens (−2,8,−2), 
bilateral posterior cingulate (2,−58,46), (−4,−50,18) and patients had significantly 
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increased activity in the bilateral insula (48,−8,−6), (−46,−2,−4).  This is shown in Fig. 3 
and Supplementary Table 2. 
 
Correlations with illness severity scores 
Linear regressions were done to test for variation in win and loss event related brain 
activity varying with symptom severity scores in the patient group alone, with particular 
attention to correlations which were consistent with between group results. In some cases 
(Supplementary Materials) between groups analyses identified large clusters of activity 
including several brain structures whereas the within patient group correlations identified 
more focal abnormalities. Identification of consistent abnormalities using different 
approaches increases the confidence in the results. Loss event images correlated 
significantly with several illness severity scores but win event images did not correlate 
significantly with any measure. 
For loss events, the BHS ‘hopelessness’ score positively correlated with bilateral 
hippocampal (−34,−26,−18), (26,−28,−24) activations, BDI depression severity 
positively correlated with hippocampal (−36,−24,−10) and insula (−36,4,6) activations 
and HAD-A anxiety correlated positively with hippocampal (−34,−34,−12) and insula 
(36,6,−8) activations. This is shown in Fig. 4 and Supplementary Table 3. 
 
Correlations with treatment resistance 
Linear regressions were done to test for variation in win and loss event related brain 
activity varying with treatment resistance scores in the patient group alone.  During loss 
events, activity in the bilateral hippocampus (−28,−16,−26), (30,−12,−26), amygdala 
(−32,6,−20) and insula (−50,10,−2) negatively correlated with MGH-S score.  During 
win events, activity in a number of regions including the hippocampus (−28,−16,−24), 
(18,−16,−20), insula (−56,10,−14), medial frontal cortex (2,61,16) and thalamus 
(0,−14,14) negatively correlated with MGH-S score.  Treatment resistance was therefore 
associated with blunted brain responses to both loss and win events.  This is shown in 
Fig. 4 and Supplementary Table 3. 
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Consistency of loss and win event activation patterns 
Feature selection, machine learning and within study replication were used to classify 
win and loss first level analysis images from MDD and control subjects. Win and loss 
images were analysed separately. Analysis using the win event images resulted in 
correctly predicting diagnostic status in 84% (sensitivity 79%, specificity 89%, χ2 = 15.3, 
P < 0.0001) of subjects. In comparison, loss event images resulted in predicting diagnosis 
correctly in 97% (sensitivity 95%, specificity 100%, χ2 = 30.5, P << 0.0001) of subjects, 
indicating greater consistency with loss event responses. A small number of brain regions 
were highlighted: the hippocampus (−27,−31,−2) was identified during the loss event 
calculation and the nucleus accumbens (−2,8,−2) plus subgenual anterior cingulate 
(−2,54,−7) during the win event classification. 
 
Discussion 
 
Deakin and Graeff predicted that the DRN is abnormally increased in activity and the 
striatum and amygdala have abnormal activity in depression (Deakin, 2013). Consistent 
with this, we found that during loss events, the DRN region (Kranz et al., 2012) was 
significantly increased in activity in MDD, as was the amygdala, and patients deactivated 
the nucleus accumbens more than controls. In addition the nucleus accumbens was 
significantly and consistently decreased in activity during win events in MDD relative to 
controls replicating previous reports (Steele et al., 2007; Kumar et al., 2008; Gradin et 
al., 2011). 
 Deakin and Graeff proposed that DRN projections act as an anticipatory anxiety 
system engaged by distal threats which facilitates learning about aversive stimuli by the 
amygdala, allowing an organism to move away from threatening stimuli by opposing 
dopamine incentive mechanisms, restraining unconditioned fight/flight (PAG) responses 
(Deakin, 2013). Concepts of perceived helplessness inform cognitive behavioural therapy 
and cognitive formulations of helplessness are predictors of depression in healthy humans 
(Alloy et al., 1999). The learned helplessness animal model of depressive illness is 
associated with marked activation of DRN neurones (Maier and Watkins, 2005; Deakin, 
2013), with large increases in extracellular 5HT from DRN projections to the amygdala 
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(Maier and Watkins, 2005). Amygdala overactivity has often been reported, particularly 
in response to aversive events, as noted in a review of studies on mood disorder (Roiser 
et al., 2012). Deakin and Graeff hypothesised that the modulatory effects of DRN 
projections to the amygdala are mediated by 5HT2c receptors, supported by recent 
animal and human studies (Deakin, 2013). Notably, an acute effect of SSRIs is often to 
increase anxiety, whilst chronic administration desensitises/down regulates post synaptic 
5HT2a/c receptors, whose activation by agonists increases anxiety-like behaviours (Van 
Oekelen et al., 2003; Maier and Watkins, 2005). 
Deakin and Graeff predicted that the hippocampus is abnormally increased in 
activity during aversive events and the MRN is abnormally decreased in activity (Deakin, 
2013). Consistent with this we found that the hippocampus was abnormally increased in 
activity in MDD due to a failure to deactivate during loss events, with the magnitude of 
the abnormality correlating with depression severity, self-report hopelessness and anxiety 
in the MDD group alone.  However we did not identify an underactive MRN region as 
anatomically defined (Kranz et al., 2012).  This might be due to the MRN having a more 
complex pattern of activity, reflecting the encoding of aversive expectation value (Amo 
et al., 2014)  
Deakin and Graeff proposed that MRN projections to the hippocampus mediate 
behavioural adaptation to repeated aversive stimuli, should anticipatory DRN 
mechanisms fail to prevent exposure (Deakin, 2013).  Studies on animals indicated that 
5HT1a receptors oppose the consolidation of aversive memories.  It was argued that the 
MRN ‘resilience’ system normally functions to interrupt rehearsal of aversive memories 
and when this fails or is underactive, ruminations result with the elaboration of negative 
semantic self-knowledge (Deakin, 2013). In this context, it is possible that abnormal 
MRN function resulted in a failure to deactivate the hippocampus on loss events, and it is 
notable that the extent of the failure to deactivate the hippocampus correlated with 
depression, self-report ‘hopelessness’ and anxiety. Hopelessness about the future has long 
been considered a critical part of depressive illness empirically linked to suicidal 
behaviour (Beck et al., 1990) and rumination is associated with increased hopelessness 
(Lavender and Watkins, 2004). A recent review concluded that the predominant weight 
of evidence supports the hypothesis that postsynaptic 5HT1a receptor binding/density is 
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reduced in the amygdala-hippocampal complex in depression (Savitz and Drevets, 2013).  
The hippocampus is often activated with the amygdala in response to fear inducing 
stimuli (Williams et al., 2001; Surguladze et al., 2003) and is associated with behavioural 
inhibition (Gray and McNaughton, 2000), acute administration of an SSRI to healthy 
subjects reduced hippocampal activation to fear-relevant stimuli (Harmer et al., 2006) 
and treatment-responsive depressive illness was associated with decreased hippocampal 
activation to sad facial expressions (Fu et al., 2004).  A recent review concluded that 
chronic stress promotes depression via. monoamine changes and suppression of 
hippocampal neurogenesis (Mahar et al., 2014), and a neuroimaging meta-analysis 
reported a reduced volume of the hippocampus and other emotion linked regions (Arnone 
et al., 2012), making relatively increased hippocampal activity in MDD notable.  
Abnormal hippocampal activity in relation to loss events was particularly consistent in 
patients with treatment-resistant MDD. In contrast, blunted responses to win events were 
not as consistent. 
Deakin noted that the hypothesis of an overactive DRN with effects on the 
amygdala and striatum is a strong test of the Deakin and Graeff theory of depression 
because its highly improbable according to a contrary view of depression as a serotonin 
deficiency disorder (Deakin, 2013). In choosing to study treatment-resistant MDD 
because of its remarkable associated disability (Whiteford et al., 2013) we considered it 
unethical to discontinue medications as a patient’s illness might worsen and not improve 
on reinstatement, as can be observed clinically. The neural responses to aversive and 
rewarding events in medicated treatment-resistant MDD were clearly abnormal, with the 
former increased and the latter decreased as reported in unmedicated patients, in contrast 
to antidepressant changes which occur in treatment-responsive illness (Ma, 2014).  
Notably, Deakin and Graeff predicted in 1991 that SSRIs would not be effective 
antidepressants because they should enhance activity in the DRN system and promote 
anxiety (Deakin, 2013). It is now known that whilst an initial increase in anxiety can 
indeed occur and may be linked to this mechanism, chronic antidepressant treatment can 
desensitise/down regulate DRN projection post synaptic 5HT2a/c receptors (Maier and 
Watkins, 2005). 
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The anterior insula is associated with emotional evaluation and is strongly 
activated during negative affect (Hester et al., 2010; Palminteri et al., 2012), anxiety and 
avoidance learning (Paulus and Stein, 2006; Samanez-Larkin et al., 2008). Increased 
insula activation in response to aversive stimuli has been reported in young people at 
familial risk of depression (Samanez-Larkin et al., 2008).  We found significantly 
increased anterior insula activation in response to loss events in MDD which correlated 
positively with self-rated depression severity (BDI) and anxiety (HAD-A), and negatively 
with treatment-resistance (MGH-S).  Therefore, in contrast to illness severity which 
correlated positively with abnormally increased activation during loss events, treatment-
resistance was associated with blunted responses to loss and win events in the 
hippocampus, amygdala and insula but not DRN.  If the therapeutic action of 
antidepressants is to reduce abnormally increased activation to aversive events and 
increase activation to reward events (Ma, 2014) this implies that the former but not the 
latter occurs in treatment-resistant illness, at least for the medial temporal lobe and insula.  
Notably though, there was not a significant correlation between treatment resistance and 
illness severity measures, implying a dissociation between hippocampal-insula brain 
activity and illness severity during loss events, which requires further investigation. 
In summary, the neuroimaging results were consistent with a range of Deakin and 
Graeff’s predictions for treatment-resistant MDD. Abnormally increased hippocampal 
activity during loss events was particularly consistent and associated with self-report 
depression, hopelessness and anxiety. Brainstem serotonergic nuclei abnormalities in 
MDD merit further study. 
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Figures 
 
Figure 1. Summary of the reward and loss-avoidance instrumental paradigm. Examples 
of (A) win pair, (B) control pair, (C) loss pair, counterbalanced across subjects. 
 
Figure 2. Loss events. (A) DRN activation in patients, (B) DRN region of interest (Kranz 
et al., 2012), (C) increased DRN activation in patients compared to controls, (D) 
increased bilateral hippocampal activity in patients compared to controls.  (E) nucleus 
accumbens deactivation in patients, (F) increased nucleus accumbens deactivation 
compared to patients. All regions significant at P < 0.01 whole brain corrected. 
 
Figure 3. Win events. (A) Activation in controls in response to win events, (B) 
significantly decreased activation in patients compared to controls during win events.  All 
regions significant at P < 0.01 whole brain corrected. 
 
Figure 4 Illness severity, treatment-resistance and consistent abnormalities.  (A) Loss 
events - BHS 'hopelessness' positively correlating with hippocampus, (B) Loss events - 
BDI depression positively correlating with hippocampal and insula activity, (C) Loss 
events - HAD-A anxiety positively correlating with hippocampal activity, (D) Loss 
events - MGH-S treatment resistance negatively correlating with bilateral hippocampus 
and amygdala, (E) Win events - MGH-S treatment resistance negatively correlating with 
bilateral hippocampus, (F) Win events - MGH-S treatment resistance negatively 
correlating with medial frontal cortex and thalamus.  All regions significant at P < 0.01 
whole brain corrected.  (G) Hippocampal region with consistently abnormal activity in 
patients during loss events, (H) nucleus accumbens and inferior medial frontal cortex 
regions with consistently blunted activity in patients during win events. 
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Table 1: Clinical and task performance descriptors for the patient and control groups. 
Variables are shown as mean (standard deviation). *chi-square test with other tests being 
t-tests. 
 
 TRD Controls  
Age 50.79 (10.6) 46.14 (13.97) n.s. 
IQ 122.58 (4.78) 116.95 (27.38) n.s. 
Female/Total* 15/19 15/21 n.s. 
HAM-D 16.00 (5.72) 0.48 (0.93) < 0.001 
MADRS 22.05 (7.93) 0.48 (1.03) < 0.001 
BDI 32.42 (11.65) 0.43 (0.87) < 0.001 
HAD-A 11.26 (3.93) 1.62 (1.47) < 0.001 
BHS 14.05 (5.36) 1.43 (1.47) < 0.001 
MGH-S 13.24 (10.78) N/A N/A 
Number of times won 33.58 (4.96) 34.90 (4.35) n.s. 
Number of times lost 29.05 (4.97) 29.10 (3.71) n.s. 
Total task score 4.53 (6.45) 5.81 (5.78) n.s. 
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Supplementary Material 
 
Supplementary Table 1: Loss trials results (see Figure 2). 
 
Within group: 
 
Region MNI coordinates T-score 
  
Resampled voxels 
per cluster 
 x y z   
Controls (activations) 
Insula 38 16 −18 3.14 301 
 −40 18 −24 2.72 188 
Controls (deactivations) 
Cluster containing 
subgenual anterior 
cingulate, hippocampus 
and nucleus accumbens 
−10 22 −10 6.09 71189 
12 24 −12 3.24 
34 −26 −10 4.24 
−32 −26 −10 3.96 
−10 6 −10 5.91 
12 8 −14 4.13 
Patients (activations) 
Insula 38 18 8 2.38 1010 
Cluster containing insula 
and amygdala 
−42 18 −2 3.74 6271 
−28 −6 −8 2.26 
DRN/PAG 0 −20 −2 4.79 1431 
Patients (deactivations) 
Cluster containing 
subgenual anterior 
cingulate and nucleus 
accumbens 
−12 36 −10 4.25 5056 
14 34 −6 3.76 
10 16 −10 6.44 
−8 14 −6 4.16 
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Between group: 
 
Region MNI coordinates T-score Resampled voxels 
per cluster 
 x y z   
Patients > Controls 
Cluster containing 
DRN/PAG, 
hippocampus, amygdala 
and insula 
0 −20 −2 2.30 32651 
−32 −28 −10 3.34 
−28 −6 −8 2.85 
46 −2 2 3.37 
−46 −2 2 3.45 
Controls > Patients 
Nucleus accumbens 10 16 −10 2.75 352 
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Supplementary Table 2: Win trials results (see Figure 3) 
 
Within group: 
 
Region MNI coordinates T-score Resampled 
voxels per 
cluster 
 x y z   
Controls (activations) 
Cluster containing 
nucleus 
accumbens/inferior 
caudate, subgenual 
anterior cingulate and 
posterior cingulate 
−2 8 −2 3.97 41870 
−12 8 −8 3.65 
12 10 −10 3.77 
−4 52 −8 5.71 
−2 −16 40 4.81 
 −6 −50 24 4.98 
Controls (deactivations) 
Lateral cortical regions 50 22 14 2.22 295 
−42 20 28 2.76 667 
−40 −60 48 3.14 1101 
Patients (activations) 
Subgenual anterior 
cingulate 
−14 58 0 3.38 178 
10 46 −2 2.46 670 
Clusters containing 
insula, amygdala and 
hippocampus 
50 0 0 3.20 1856 
26 0 −12 2.37 
42 −16 −10 2.77 
 −48 4 −6 2.83 1239 
 −28 2 −16 2.37 
 −30 −14 −10 2.86 
Patients (deactivations) 
Dorsolateral prefrontal 
cortex 
44 16 26 2.88 873 
−58 20 26 4.54 1938 
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Between group: 
 
Region MNI coordinates T-score Resampled 
voxels per 
cluster 
 x y z   
Patients > Controls      
Insula 48 −8 −6 3.17 294 
 −46 −2 −4 2.24 442 
Controls > Patients      
Cluster containing 
subgenual anterior 
cingulate and nucleus 
accumbens 
−2 52 4 2.66 10871 
−2 8 −2 3.15 
Posterior cingulate 2 −58 46 2.86 4726 
−4 −50 18 2.91 
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Supplementary Table 3: Patients’ correlation results (see Figure 4). 
 
Within group: 
 
Region MNI coordinates T-score 
  
Resampled voxels 
per cluster 
 x y z   
BHS (positive correlations with loss events) 
Hippocampus −34 −26 −18 4.82 1463 
 26 −28 −24 3.25 830 
BDI (positive correlations with loss events) 
Hippocampus −36 −24 −10 2.85 2124 
Insula −36 4 6 2.66 485 
HAD-A (positive correlations with loss events) 
Hippocampus −34 −34 −12 4.15 4038 
Insula 36 6 −8 2.91 3623 
MGH-S (negative correlations with loss events) 
Cluster containing 
hippocampus, amygdala 
and insula 
−28 −16 −26 3.60 29544 
30 −12 −26 2.70 
−32 6 −20 4.65 
−50 10 −2 2.90 
MGH-S (negative correlations with win events) 
Cluster containing 
hippocampus, insula, 
medial frontal cortex and 
thalamus 
−28 −16 −24 5.81 55233 
18 −16 −20 5.33 
−56 10 −14 4.86 
2 61 16 4.52 
0 −14 14 6.15 
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